Carregant...
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
SIMPLE SUMMARY: Due to the lack of selectivity and the severe side-effects, cytostatics are the drugs of the present but not of the future and consequently new anticancer strategies must be developed. After binding to the neurokinin-1 receptor (NK-1R), NK-1R antagonists exert antitumor actions (anti...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564414/ https://ncbi.nlm.nih.gov/pubmed/32962202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12092682 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|